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Abstract
Background: The prevalence of tobacco smoking in Germany is high (~27%). Monitoring of national patterns of
smoking behaviour and data on the “real-world” effectiveness of cessation methods are needed to inform policies
and develop campaigns aimed at reducing tobacco-related harm. In England, the Smoking Toolkit Study (STS) has
been tracking such indicators since 2006, resulting in the adaptation of tobacco control policies. However, findings
cannot be directly transferred into the German health policy context. The German Study on Tobacco Use (DEBRA:
“Deutsche Befragung zum Rauchverhalten”) aims to provide such nationally representative data.
Methods/Design: In June 2016, the study started collecting data from computer-assisted, face-to-face household
interviews in people aged 14 years and older. Over a period of 3 years, a total of ~36,000 respondents will complete the
survey with a new sample of ~2000 respondents every 2 months (=18 waves). This sample will report data on
demographics and the use of tobacco and electronic (e-)cigarettes. Per wave, about 500–600 people are expected to be
current or recent ex-smokers (<12 months since quitting). This sample will answer detailed questions about
smoking behaviour, quit attempts, exposure to health professionals’ advice on quitting, and use of cessation
aids. Six-month follow-up data will be collected by telephone.
Discussion: The DEBRA study will be an important source of data for tobacco control policies, health strategies, and
future research. The methodology is closely aligned to the STS, which will allow comparisons with data from England,
a country with one of the lowest smoking prevalence rates in Europe (18%).
Trial registration: This study has been registered at the German Clinical Trials Register (DRKS00011322) on 25th
November 2016.
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Background
In Germany, 110,000 people die from smoking tobacco
each year [1]. In total, 13% of the country’s mortality is
attributable to smoking [1]. While the implementation
of various tobacco control policies has led to a reduction
in smoking prevalence in high-income countries such as
in England (current prevalence = 18%) [2], the preva-
lence in the German adult population is still high (27%)
[3]. Like in other countries, smoking prevalence is con-
siderably higher in low income smokers [4, 5], which
results in substantial health inequalities between higher-
and lower- income groups [6].
Monitoring of national patterns of smoking and quit-
ting behaviour is needed to inform policies and develop
successful campaigns aimed at reducing tobacco-related
harm. Relevant parameters to monitor include: smoking
prevalence; rates, duration, trigger and success of quit
attempts; exposure to health professionals’ advice on
quitting; the use of harm reduction strategies such as
“cutting down”; and the use of cessation aids [7]. Demo-
graphic information such as gender or socioeconomic
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status (SES) and the influence of potential confounders
on the smoking cessation process, e.g., the motivation to
stop or the degree of nicotine dependence, also have to
be considered [7].
Several national large-scale surveys (ongoing or already
completed) [4, 8–10] have been providing useful data on
tobacco consumption and smoking behaviour in Germany,
but they all have limitations. First, these surveys cover a
wide range of addictions and other health topics in general
which means that they do not allow for in-depth analysis of
data on smoking behaviour. Second, these surveys collect
data only on an annual or even less frequent basis. Data are
therefore often out of date, and there is a lack of flexibility
to adjust survey items to new, specific trends in smoking
behaviour (e.g., the introduction of electronic (e-)cigarettes).
This limits their topical relevance for tobacco control
policies and research. Third, the sample sizes of some
of these surveys are not sufficiently large to allow sta-
tistically reliable analyses.
Collection of observational “real-world” data on the
effectiveness of smoking cessation methods is important to
supplement randomised controlled trials (RCTs), whose
generalisability is somewhat limited because of the partici-
pant selection criteria. There is good evidence from RCTs
that behavioural support and pharmacological treatment,
such as nicotine replacement therapy (NRT), bupropion, or
varenicline, improve the success of quit attempts [11–15].
However, analyses on the real-world effectiveness of smok-
ing cessation methods from the observational Smoking
Toolkit Study (STS) from England [16] showed, for ex-
ample, that smokers who buy NRT over the counter to
aid their quit attempt have similar odds of success as
those who tried to stop unaided [17], indicating the im-
portance of providing cessation medication together with
behavioural support. The STS is a large ongoing cross-
sectional household survey which provides monthly data
as well as six-month follow-up data on smoking and ces-
sation behaviour in the English general population aged
16 years and older [16]. Findings from the STS cannot be
directly transferred to the German health policy context.
Whereas behavioural support and pharmacological smok-
ing cessation treatment, for instance, is offered at no or
minimal cost in England, such services do not exist in
Germany, and evidence-based treatments are not or only
partly reimbursed.
Moreover, little is known about the real-world effective-
ness of e-cigarettes for smoking cessation in the German
population. Its popularity and usage has rapidly increased
in recent years. In England, for example, the prevalence of
“ever-users” (people who used an e-cigarette at least once)
in smokers and recent ex-smokers has increased from
approximately 2% in 2011 to approximately 25% in 2016
[2]. Data from Germany show a comparable trend [3, 18].
Due to design and variety of flavours, e-cigarettes appear
popular among adolescents. Authors have debated whether
or not e-cigarettes may facilitate nicotine addiction in this
age cohort [19, 20]. Therefore, tracking e-cigarette usage
behaviour in adolescents is of particular importance.
Aims
The DEBRA study will fill a crucial gap in the literature
by collecting up-to-date and in-depth data on key indi-
cators regarding the patterns and trends of smoking and
quitting in the German population, helping to guide policy
and clinical practice. The collection of baseline and follow-
up data provides the possibility for longitudinal analyses on
within-individual trends in relevant parameters. These data
can contribute to a better understanding of smoking cessa-
tion processes in the general population and the role played
by triggers such as motivation or physician advice, sociode-
mographic factors, and aids to cessation such as NRT,
behavioural support, or even non-evidence-based methods,
including e-cigarettes. The methodology of DEBRA is
closely aligned to the STS, allowing comparisons with
relevant data from the English population. The study
design allows a flexible adjustment of the scope of the
survey to address emerging questions relevant to policy
changes, practice or research.
Methods
Design and sample
The DEBRA study started in June 2016 to collect data
from computer-assisted face-to-face household inter-
views of people aged 14+. Over a period of 3 years, every
two months, a new sample of approximately 2000
respondents will complete the survey (= 18 waves, ap-
proximately 36,000 respondents in total). Per wave,
about 500–600 people are expected to smoke tobacco or
to be recent ex-smokers (i.e., have smoked in the past
12 months). It is anticipated that data on approximately
10,000 smokers and recent ex-smokers will be collected
during the 3-year period. All smokers and recent ex-
smokers who are willing to be re-contacted will be
followed-up at 6 months following baseline by telephone
to complete a short survey. It is expected that about
120–150 (25%) from each baseline wave will agree to be
followed-up, resulting in a total sample size of approxi-
mately 2500 respondents with baseline and follow-up
data.
The fieldwork is conducted by the market research
institute Kantar Health Munich, Germany. The investi-
gation area is the Federal Republic of Germany. The
total population of the study covers all German speak-
ing persons aged 14 years or over who live in private
households during the survey period. To keep the costs
manageable, the baseline survey will use a multi-topic
omnibus survey, a regular series of surveys from Kantar
Health to which questions can be added. Per wave up
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to 280 trained interviewers will conduct on average 7
interviews each. Questions of the DEBRA study are placed
in the middle of the 1 h multi-topic omnibus survey.
Baseline data collection will be facilitated through multi-
stage, multi-stratified random probability sampling. Firstly,
all communities within Germany will be stratified by the
following regional attributes: federal state (n = 16), adminis-
trative districts (a maximum of n = 41 per federal state),
and type of community (a maximum of n = 10 per district).
For stratification purposes, these attributes will be used in
combination. Hence, each type of community in every
administrative district builds a different stratum, which
theoretically leads to a total of 410, in practice fewer, strata.
To determine the primary sampling units for the study,
the geographical area of Germany was divided into 53,000
small areas of approximately equal size, based on commu-
nities, and using geographic street mapping system soft-
ware. For each small area, the sample size was determined
in proportion to the total number of households in the
area, relative to the total number of households in the
whole population. This is called an area sample or sample
point. In the current study the number of sample points
varies between 360 and 410. All small areas were also allo-
cated to their superordinate geographical units, such as
rural and urban districts and municipalities, to allow fur-
ther stratification of the sample. Sampling units of the sec-
ond stage will be represented through private households
and selected by a random walk procedure. Sampling units
of the third stage will be the target persons themselves.
These will be selected using a random process (so called
“Schwedenschlüssel”), which gives an equal chance of
selection to every eligible person within a household [21].
Weighting techniques
Data analyses will take into account weighting adjustments
for personal and household characteristics. According to
the multi-stage sampling procedure of baseline data the
weighting has to be done in separate stages, too. One has
to differentiate between the so-called design weighting,
which corrects unequal selection probabilities due to the
sample design, and the outcome weighting, which corrects
disproportions based on the structure of target persons
who did or did not participate in the survey. Step 1 and
step 3 (see further on) are calculated as rim-weighting
within an iterative process. Step 2 is calculated by an analyt-
ical approach.
First step (outcome weighting)
The sampling procedure gives every household the same
chance to be selected which means that the realised
sample should be distributed proportionally to the distri-
bution of private households. Within this first step, the
structure of the realised sample is compared to the pro-
portions of the original stratification of the first sampling
stage. The weighting factors correct differences between
the original and the realised household characteristics.
Second step (design weighting)
In sampling stage 3 (see below) every eligible person
within a household has the same chance of selection.
Hence, the selection probabilities of the target persons
differ across the whole sample according to the size of
the household they live in. This unequal selection prob-
ability is corrected by an analytical mathematical proced-
ure using the size of the households. The household
sample is changed into a sample of persons where every
respondent has equal selection probability.
Third step (outcome weighting)
The last weighting step corrects for differences between
the demographic structures of the respondents and the
structures of the total population using the following
structures: Federal states combined with sex and gener-
ally seven age classes.
Baseline measures
The main baseline questionnaire for the DEBRA can be
found in Additional file 1. To ensure comparability of
data, the majority of questions has been adopted from
the STS survey and labelled appropriately in the question-
naire [16]. STS questions were developed by an expert
panel and policy makers [16]. Existing questions from the
STS were translated into German and new questions were
developed by a bilingual team of researchers (see authors’
contributions) with experience in using the STS data.
Some of the validated scales from the STS were translated
and culturally adapted according to international guide-
lines [22].
Baseline DEBRA questions for each respondent cover
smoking status and ever-use of e-cigarettes. Depending on
the response behaviour, current tobacco smokers (cigarettes
or other tobacco products), recent ex-smokers (<12 months
since quitting tobacco) and ever-users of e-cigarettes or a
similar product (e.g., e-hookah, e-cigar, or e-pipe) will an-
swer on further detailed questions about smoking behavior,
quit attempts, exposure to health professionals’ advice on
quitting, and use of cessation aids (Table 1). In addition,
socioeconomic data (including age, sex, housing situation,
residential area, marital status, education, respondent
and household income, and employment status) will be
regularly collected in all respondents as part of the
omnibus survey.
The study design is flexible. Depending on trends in
population usage of tobacco or nicotine products, in
tobacco research, or tobacco control policies, it is intended
that new questions can be added from wave to wave while
others will be removed when adequate statistical power is
reached to address a specific scientific issue.
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Six-month follow-up
Smokers and recent ex-smokers who agree to be followed-
up will be re-contacted by telephone six months following
baseline. The computer assisted telephone interviews will be
performed by interviewers from Kantar Healths’ call centre
using a Sample Management System (SMS). The SMS man-
ages and controls all telephone contacts (e.g., telephone
numbers that cannot be contacted are set deferred, and pre-
sented again after a long interval at different times of a day).
Interviewers will try to reach the respondents up to ten
times at various times and on different days of the week.
Additional file 2 shows the main follow-up questionnaire
for the DEBRA study. Follow-up questions focus on current
smoking status and on detailed exploration of any quit at-
tempts that have been made during the past six months.
Methods used for a quit attempt (if so) will be asked in
concordance to the baseline survey. This prospective elem-
ent enables us to further analyse the real-world effective-
ness of smoking cessation methods using longitudinal data
[23] and providing data on within-individual trends. The
short time frame between baseline and follow-up takes into
consideration the fact that many smokers make multiple
quit attempts within a short space of time and often rapidly
forget unsuccessful ones [24]. Smokers who try to stop un-
aided, for example, seem to forget failed quit attempts more
quickly than those who use treatment, what might lead to
an underestimation of the effectiveness of stop-smoking
medications [25].
Main research topics addressed by the DEBRA study
The following research topics will be addressed from the
beginning of data collection in wave 1 (June 2016). It is
very likely that more topics will be added over time.
Prevalence rates and monitoring of trends
DEBRA will provide prevalence rates and proportions of
key parameters on smoking status, smoking behaviour,
quit attempts and their triggers, exposure to health pro-
fessionals’ advice on quitting, and use of evidence-based
as well as non-evidence-based cessation aids, including
e-cigarettes, stratified by socioeconomic factors, nicotine
dependence or motivation to quit. Longitudinal analyses
from baseline to follow-up will provide insight into within-
individual trends in each of these parameters. Time series
analyses will assess changes including seasonal trends,
linear trends, and as a function of policy changes or
media campaigns.
Social gradient in quit attempts and successful abstinence
It is important to determine causes of the higher smoking
prevalence rates in disadvantaged groups. Data from the
STS showed that smokers in more deprived socioeconomic
groups in England are just as likely as those in higher
groups to try to stop and use aids to cessation [26].
However, there is a strong gradient across socioeconomic
groups in success, with significantly lower success rates in
disadvantaged groups being half as likely to succeed com-
pared with the highest [26]. DEBRA data will examine to
what extent these findings also apply to different socioeco-
nomic groups in Germany.
External validation of the Motivation to Stop Scale (MTSS)
Smoker’s motivation to stop smoking is an important
source of information, as it predicts the incidence of
future quit attempts [27, 28]. Moreover, measuring changes
in motivation to stop on a population level is useful to
assess and to track the impact of tobacco control policies
interventions over time. For this purpose, the single-item
Table 1 Content of the baseline questionnaire for current smokers, recent ex-smokers, and e-cigarette users
Current smokers and recent ex-smokers 1. Current smoking behaviour (or past smoking behaviour in those that have recently stopped)
2. Current motivation to quit smoking using the Motivation to Stop Scale [27]
3. Use of nicotine replacement therapy while smoking
4. Current (or past) nicotine dependence using the Fagerström Test for Cigarette Dependence [29]
5. Exposure to health professionals’ advice on quitting
6. Current (or past) strength of urges to smoke [30]
7. The number of serious quit attempts recalled as having been made within the past 12 months
8. For the most recent quit attempt within the past 12 months:
a. how long-ago the quit attempt started
b. how long it lasted
c. any aids used (e.g., nicotine replacement therapy over-the-counter, telephone helpline)
d. what triggered it (external and internal triggers)
e. whether it involved cutting down gradually
f. and whether it was planned in advance [7]
E-cigarette users 1. Usage behaviour and its development
2. Starting age and reasons for e-cigarette use
3. Type, place of purchase and average consumption of liquid and nicotine in e-cigarettes
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MTSS has been developed as a valid and cost-effective tool
[27]. The MTSS combines key motivational constructs and
has been shown to be a strong and accurate predictor of
future quit attempts. With the DEBRA study, we aim to de-
termine the external validity of the translated and culturally
adapted MTSS (MRS: “Motivation zum Rauchstopp Skala”)
among German smokers in predicting future quit attempts.
External validation of the Strength of Urges to Smoke Scale
(SUTS)
An important criterion for a measure of nicotine depend-
ence is how well it predicts relapse following smoking
cessation. A commonly used scale to assess dependence
and predict relapse is the Fagerström Test for Cigarette
Dependence (FTCD) [29]. However, no representative data
have been published on the predictive validity of the
FTCD among German smokers. Furthermore, in recent
ex-smokers, dependence cannot be measured with the
FTCD, as one of its items includes the number of ciga-
rettes smoked per day. By contrast, the two-item SUTS
has been found to be a strong indicator of the severity
of nicotine dependence and to be a better predictor of
relapse than the FTCD [30] in the English population.
Its use also allows analyses on the effectiveness of cessation
methods (used during the last quit attempt) in recent
ex-smokers through adjusting for urges to smoke as a con-
founder [17]. We aim to determine the external validity of
the translated and culturally adapted SUTS (VRS:
“Verlangen zu Rauchen Skala”) among German smokers
and recent ex-smokers in measuring nicotine dependence
and predicting relapse.
Real-world effectiveness of evidence-based and non-evidence-
based smoking cessation methods, including e-cigarettes
Numerous analyses on the real-world effectiveness of
smoking cessation aids have been conducted with data
from the STS in England, for example, to supplement
RCT data and to provide estimates for the effectiveness
in the general population [17]. However, transferability
of STS results to the German health policy context is
difficult because evidence-based cessation aids are not or
only partly reimbursed in Germany. The DEBRA study
will provide such data for Germany. Moreover, hardly
any national data is available on usage and real-world
effectiveness of non-evidence-based methods, including
e-cigarettes. In England, for instance, e-cigarettes have
already become the most frequently chosen method of
quitting tobacco, possibly contributing to the country’s
decline in tobacco smoking [31]. The DEBRA study aims
at assessing the emerging role of the e-cigarette as an
aid in smoking cessation in Germany and evaluating its
real-world effectiveness to complement sparse data coming
from one existing RCT which found a clinically relevant
difference in continuous 6-month abstinence between ac-
tive vs. placebo e-cigarette users trying to quit [32].
Factors associated with the use of aids to cessation
Recent data from Germany suggest that only a small pro-
portion of smokers use evidence-based aids while trying to
quit [33]. Most smokers still try to quit unaided, which is
associated with high relapse rates, particularly within the
first weeks of abstinence where the strongest withdrawal
symptoms occur [34]. The assessment of differences in
sociodemographic or smoking characteristics might sup-
port health strategies to address specific groups of smokers
who are underutilising evidence-based cessation aids in
health strategies to a greater extent [35]. Therefore, the
DEBRA study aims to analyse variations in use of smoking
cessation aids among German smokers trying to quit.
Exposure to health professionals’ advice on quitting
Brief advice on smoking cessation delivered by a physician
has been found to be effective and affordable [36, 37].
Hence, clinical practice guidelines recommend implement-
ing brief advice on smoking cessation into routine primary
care to assist a large number of smokers. Nevertheless,
these recommendations seem to be only rarely imple-
mented into practice in Germany [38] and hardly any
representative and up-to-date data is available on fre-
quency of delivery and approaches used to deliver such
advice. The DEBRA study aims to provide such nation-
ally representative data to inform policy health strat-
egies aimed at implementing the clinical guidelines.
Data analysis and sample size calculation
Statistical data analyses depend on scientific issues that
will be addressed by the DEBRA study. Detailed analyses
will therefore be reported in the publication of each future
study, respectively.
The methodology of DEBRA is closely aligned to the
English STS. Our assumptions about expected means
and variances for the primary analyses are therefore
made on the basis of these STS analyses [17, 23, 39, 40].
Data indicate that, depending on the specific issue, a
sample between 1500 and 7000 interviewed smokers and
recent ex-smokers are needed to yield adequate statistical
power of >80%. The total required sample size was deter-
mined considering current prevalence rates of smokers in
Germany [4], available data on rates of cessation attempts
within the past 12 months [33], and physician visits within
the past 12 months [41], whereas average response rates
at follow-up were estimated by Kantar Health on the basis
of previous surveys. During the 18 waves of the DEBRA
study with approximately 2000 interviews per wave, about
500–600 people are expected to smoke tobacco or to be
recent ex-smokers (in total = ~10,000). Based on these as-
sumptions the required baseline sample sizes from a total
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of 1500 to 7000 smokers and recent ex-smokers can be
achieved within 3 years. A response rate of 20–25% is
expected at follow-up, resulting in a sample size of
approximately 2500 after 3 years.
Dissemination of findings
Findings from this survey will be reported in national
and international peer-reviewed scientific journals, and
at national and international conferences. Up-to-date
statistics will be also published on the study website:
www.debra-study.info.
Discussion
Reducing the prevalence of tobacco smoking is one of
the most important strategies for reducing the burden
of morbidity, premature death, and health inequalities
between higher and lower income groups within the
next decades [42]. Continuous monitoring of national
patterns of smoking and quitting behaviour as well as
real-world data on the effectiveness of smoking cessation
methods are needed to guide tobacco control policies and
clinical practice.
The DEBRA study aims to provide such representative
data for Germany. Its methodology is sufficiently flexible
to allow adaptions of its research scope and tracking
data on every two months permits a much more sensitive
test of the possible effects of interventions than can be
achieved by annual national surveys. Hence, DEBRA data
will provide quick and direct estimates of policy or health
strategy impacts aimed at reducing tobacco-related harm
as well as of its cost-effectiveness.
The results of the DEBRA study can also be relevant
to improve clinical care for smokers. Real-world data
on the effectiveness of smoking cessation aids might
complement the current state of knowledge on
evidence-based and non-evidence-based smoking ces-
sation processes which is usually obtained from RCTs.
Data on prevalence of the use of such methods and on
exposure to health professionals’ advice on quitting
might help to analyse the as-is state of usage and care.
Future interventional studies might then address dis-
crepancies between the as-is (e.g., under-usage of
evidence-based treatments to aid cessation) and the
target state of use (e.g., use of evidence-based treat-
ments). Such interventions could address both, the
physicians and the patients themselves, to increase
rates of recommendations as well as the use of
evidence-based cessation aids.
We expect the DEBRA methodology to be robust and
reliable. However, data from the first waves will have to
be analysed to compare the representativeness of the
DEBRA data to other ongoing national large scale sur-
veys [4, 8–10]. Slight deviations can certainly occur due
to different modes of data collection (face-to-face
interview, telephone, or online), seasonal fluctuations,
differences in weighting procedures, as well as differ-
ences due to the inclusion of diverse age groups of
participants.
There are certain general limitations that apply to
large national surveys such as the DEBRA study, in-
cluding those associated with self-report which may
be biased or inaccurate. Furthermore, drop-out rates
from baseline to six month follow-up are expected to
be substantial and possibly differential. However, rep-
resentativeness of the follow-up samples will be ex-
amined in detail by comparisons with baseline data
on key variables from those not followed up and re-
sults from such analyses will be interpreted accord-
ingly. Finally, even if the DEBRA study aims to
collect a sample of smokers large enough to yield ad-
equate statistical power for several subgroup analyses,
certain analyses are likely to be underpowered due to
small sample sizes, e.g. in relation to ethnicity, specific
professions, or usage of specific e-inhalation products
(e.g., e-hookah, e-cigar, or e-pipe).
Conclusions
The DEBRA study will enhance understanding of factors
influencing smoking and cessation behaviour on a popula-
tion level and be an important resource of scientific data
for the development of tobacco control policies, health
strategies, and future studies in Germany. The study design
allows a flexible adjustment of the scope of the survey to
specific trends in smoking behaviour, topical questions in
tobacco research or policies. The methodology of the study
is closely aligned to the STS, allowing international
comparisons of data.
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